What changed
2026-08-06 06:22 UTC → 2026-08-07 02:02 UTC ·
added
removed
BioNTech restructuring, oncology shift and losses shift, revenue cut
BioNTech’s In August 2026 restructuring accelerated after a May AGM where 92 % of shareholders approved the closure of its Mainz and Singapore COVID‑19 vaccine sites, a cut of roughly 1,860 jobs and the planned exit of co‑founders Ugur Şahin and Özlem Türeci by year‑end. The announcement triggered an 18 % share‑price fall and prompted union IG BCE to denounce the lack of transparent consultation over the plant closures in Idar‑Oberstein, Marburg, Singapore and the former CureVac facilities. The company’s acquisition of CureVac led to a task‑force with Baden‑Württemberg ministries to manage the shutdown of the Tübingen R&D site, slated for 31 December 2026, with two‑thirds of staff facing termination. BioNTech pledged a socially‑responsible support programme for affected employees. On the oncology front, BioNTech filed an FDA application for the antibody‑drug conjugate BNT323 (trastuzumab pamirtecan) targeting HER2‑positive endometrial cancer, reporting a 47.9 % overall response rate in mid‑stage data and higher efficacy in the strongest HER2‑expressing subgroup. The bispecific antibody BNT327 (Pumitamig), co‑developed with Bristol Myers Squibb, continues to progress in Phase III trials for lung and breast cancer and holds Fast‑Track and Breakthrough‑Therapy designations. A €500 million annual‑cost‑saving programme, including the possible sale or closure of up to four German sites, is intended to fund the personalized cancer‑medicine platform. Moderna has signalled interest in acquiring some German plants, contingent on a favourable European policy environment. Financially, BioNTech posted a H1 further cut its 2026 loss of €1.35 billion and, in Q2, revenue outlook to €1.6‑1.9 billion, confirming a Q2 net loss of €820.8 million with revenue falling 59.5 and a 60 % drop in revenue to €105.6 million. The full‑year 2026 revenue outlook was trimmed Shares fell to €1.6‑1.9 billion. €79.15, about 6 % below the 200‑day average, and Citigroup lowered its price target to $125 while keeping a buy rating. The supervisory board named confirmed Guido Oelkers as Oelkers, former CEO effective of Swedish Orphan Biovitrum, will assume the chief‑executive role on 1 February 2027, succeeding co‑founder Şahin, who together with Ugur Şahin. Şahin and Özlem Türeci will leave operational duties by year‑end to launch an independent mRNA‑innovation venture, while venture in which BioNTech retains a minority stake. The firm reiterated its pivot to oncology, spotlighting late‑stage candidates BNT327 (Pumitamig) and BNT323, and said it holds a cash and liquid‑asset buffer of roughly €16.6 billion to fund the transition. It also announced the planned closure of the Idar‑Oberstein, Marburg and Tübingen sites by the end of 2027 and the winding down of Singapore operations in early 2027. The industrial union IGBCE urged a sale rather than closure of the Marburg plant, noting reported interest from Moderna.